Editorial Board About Us

Prostate-specific antigen doubling time

All articles from this key word are listed below.

Volume 8, Supplement 2 Review Articles

Monitoring Response, Prediction Methodology, Staging, and Imaging in Prostate Cancer

16th International Prostate Cancer Update

David Pomerantz Nicholas Vogelzang

The predictive values of various tests and examinations are assessed as they relate to prostate cancer progression and treatment. The usefulness of post-treatment biopsy specimens is greatest 2 years after radiation therapy completion. Gleason grading is not reliable in the setting of hormonal ablation therapy. For patients with extracapsular extension, the survival curves separate depending on whether positive or negative surgical margins are obtained. Prostate-specific antigen doubling time is increasingly used as an indicator of disease recurrence after local therapy and prostate cancer–specific survival. [Rev Urol. 2006;8(suppl 2):S30-S34]

Prostate cancer Immunotherapy Prostate-specific antigen Predictive modeling Prostate-specific antigen doubling time

Volume 8, Supplement 2 Review Articles

Prostate Cancer: Epidemiology, Screening, and Biomarkers

16th International Prostate Cancer Update

Gerald W Chodak

Carcinoma of the prostate continues to be a major health problem in the United States. Beginning in 1988, a marked increase in detection of prostate cancer occurred due to the development of a test for prostate-specific antigen (PSA). Controversy exists, however, about the value of PSA as a tumor marker. Although it has prognostic significance both before and after definitive therapy for prostate cancer, it is unclear whether routine PSA screening will translate into a survival advantage for patients. Because of its limitations, PSA may not ultimately be a good enough marker to be used as a screening tool. However, molecular biology has led to a rapid rise in the number of potential new prostate tumor markers, which may eventually overcome the weaknesses of PSA. Considerable progress has occurred in the diagnosis and management of prostate cancer: more is understood about the risk factors for the disease, possible ways to prevent it, and new ways to diagnose and monitor it. These developments have already translated into better patient care, while also identifying where further improvements are needed. [Rev Urol. 2006;8(suppl 2):S3-S8]

Prostate cancer Prostate-specific antigen Biomarkers Prostate-specific membrane antigen Prostate-specific antigen doubling time